CA3140285A1 - Treatment of tlr-4 mediated diseases and conditions with aptamers targeting tlr-4 - Google Patents

Treatment of tlr-4 mediated diseases and conditions with aptamers targeting tlr-4 Download PDF

Info

Publication number
CA3140285A1
CA3140285A1 CA3140285A CA3140285A CA3140285A1 CA 3140285 A1 CA3140285 A1 CA 3140285A1 CA 3140285 A CA3140285 A CA 3140285A CA 3140285 A CA3140285 A CA 3140285A CA 3140285 A1 CA3140285 A1 CA 3140285A1
Authority
CA
Canada
Prior art keywords
aptamer
tlr
aptoll
present disclosure
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3140285A
Other languages
English (en)
French (fr)
Inventor
David Segarra De La Pena
Lisardo Bosca Gomar
Ignacio Lizasoain Hernandez
Fernando De Castro Soubriet
Carlos ZARAGOZA
Macarena Hernandez Jimenez
David Pineiro Del Rio
Beatriz Fernandez Gomez
Maria Angeles Moro Sanchez
Diego Perez Rodriguez
Maria Eugenia Zarabozo Leal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aptatargets SL
Original Assignee
Aptatargets SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptatargets SL filed Critical Aptatargets SL
Priority to CA3291318A priority Critical patent/CA3291318A1/en
Publication of CA3140285A1 publication Critical patent/CA3140285A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3140285A 2019-05-16 2020-05-16 Treatment of tlr-4 mediated diseases and conditions with aptamers targeting tlr-4 Pending CA3140285A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3291318A CA3291318A1 (en) 2019-05-16 2020-05-16 Treatment of tlr-4 mediated diseases and conditions with aptamers targeting tlr-4

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962849068P 2019-05-16 2019-05-16
US201962849072P 2019-05-16 2019-05-16
US62/849,068 2019-05-16
US62/849,072 2019-05-16
EP19382425 2019-05-27
EP19382424 2019-05-27
EP19382425 2019-05-27
EP19382424 2019-05-27
PCT/IB2020/054655 WO2020230109A1 (en) 2019-05-16 2020-05-16 Treatment of tlr-4 mediated diseases and conditions with aptamers targeting tlr-4

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3291318A Division CA3291318A1 (en) 2019-05-16 2020-05-16 Treatment of tlr-4 mediated diseases and conditions with aptamers targeting tlr-4

Publications (1)

Publication Number Publication Date
CA3140285A1 true CA3140285A1 (en) 2020-11-19

Family

ID=73288968

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3140285A Pending CA3140285A1 (en) 2019-05-16 2020-05-16 Treatment of tlr-4 mediated diseases and conditions with aptamers targeting tlr-4
CA3291318A Pending CA3291318A1 (en) 2019-05-16 2020-05-16 Treatment of tlr-4 mediated diseases and conditions with aptamers targeting tlr-4

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3291318A Pending CA3291318A1 (en) 2019-05-16 2020-05-16 Treatment of tlr-4 mediated diseases and conditions with aptamers targeting tlr-4

Country Status (7)

Country Link
US (2) US20220233572A1 (https=)
EP (1) EP3969011A1 (https=)
JP (2) JP7789563B2 (https=)
CN (1) CN113966220A (https=)
AU (1) AU2020276703A1 (https=)
CA (2) CA3140285A1 (https=)
WO (2) WO2020230109A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12390172B2 (en) * 2021-02-19 2025-08-19 Canon Medical Systems Corporation Method and apparatus for displaying medical images
WO2024064288A1 (en) * 2022-09-22 2024-03-28 Thomas Jefferson University Tlr4 inhibitors for cancer treatment
IL321911A (en) 2023-01-05 2025-09-01 Merck Patent Gmbh Aptol molecules for the treatment of ischemic stroke and intracranial hemorrhages
AU2024275027A1 (en) 2023-05-22 2025-12-11 Merck Patent Gmbh New tlr-4 antagonist aptamers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JPH088933B2 (ja) * 1987-07-10 1996-01-31 日本ゼオン株式会社 カテ−テル
SG10201406016SA (en) 2006-04-03 2014-11-27 Stella Aps Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
DK2149605T3 (da) 2007-03-22 2013-09-30 Santaris Pharma As Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
ES2599979T3 (es) 2009-04-24 2017-02-06 Roche Innovation Center Copenhagen A/S Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
EP2619189B1 (en) 2010-09-24 2020-04-15 Zoetis Services LLC Isoxazoline oximes as antiparasitic agents
ES2555160B1 (es) 2014-06-24 2016-10-25 Aptus Biotech, S.L. Aptámeros específicos de TLR-4 y usos de los mismos
WO2020069313A2 (en) * 2018-09-28 2020-04-02 Henry Ford Health System Use of extracellular vesicles in combination with tissue plasminogen activator and/or thrombectomy to treat stroke

Also Published As

Publication number Publication date
JP7789563B2 (ja) 2025-12-22
JP2022533966A (ja) 2022-07-27
WO2020230108A1 (en) 2020-11-19
CN113966220A (zh) 2022-01-21
US20220233572A1 (en) 2022-07-28
CA3291318A1 (en) 2026-03-02
JP2025148491A (ja) 2025-10-07
EP3969011A1 (en) 2022-03-23
US20220233570A1 (en) 2022-07-28
WO2020230109A1 (en) 2020-11-19
AU2020276703A1 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
JP7789563B2 (ja) Ｔｌｒ－４を標的とするアプタマーによるｔｌｒ－４媒介性の疾患および状態の治療
JP7398007B2 (ja) Ａｎｇｐｔｌ３発現を阻害する組成物及び方法
JP6899509B2 (ja) 呼吸器疾患関連遺伝子特異的ｓｉＲＮＡ、そのようなｓｉＲＮＡを含む二重らせんオリゴＲＮＡ構造体およびこれを含む呼吸器疾患予防または治療用組成物
JP6768701B2 (ja) Ｃ／ＥＢＰアルファｓａＲＮＡ組成物および使用方法
US20170073679A1 (en) Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Cell Types
JPWO2013047844A1 (ja) Ｎｇｆに対するアプタマー及びその用途
JP2025516306A (ja) 中枢神経系送達用の脂質ナノ粒子製剤
US20250263705A2 (en) Pharmaceutical combinations for treatment of hbv
JP2025163035A (ja) 筋再生および筋成長
US20240279667A1 (en) Compositions and methods of treating diseases associated with bile acid transporter
US12458657B2 (en) Neurogenesis
TW202540420A (zh) 用於抑制LPA的基因表現的siRNA，含其的組合物及其用途
WO2025191002A1 (en) Treatment and prevention of disease by il-7r inhibition
TW202220675A (zh) 降低ｚ－ａａｔ蛋白水準之方法
JP7535315B2 (ja) Ｈｉｃ－５インヒビターの新規用途
WO2023014724A2 (en) Scaffold matrix attachment regions for gene therapy
TW202330920A (zh) 用於調節ａｐｏｃ３表現之組合物及方法
WO2025252223A1 (zh) 一种抑制PCSK9基因表达的RNAi制剂及其应用
JP2025512445A (ja) Ｓｃａｐ活性を調節するための組成物及び方法
WO2026061490A1 (zh) 用于抑制FXII基因表达的siRNA及其缀合物和用途
WO2025231388A1 (en) Methods and compositions for treating pompe disease
WO2025104709A1 (en) Microrna-378a-3p antisense oligonucleotides and uses thereof
CN119654413A (zh) Itfg1抑制性核酸
TW202546228A (zh) 用於抑制胰島素樣生長因子１受體表達的ｒｎａ抑制劑
CN118922540A9 (zh) 前激肽释放酶调节组合物及其使用方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231228

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250509

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250509

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250704

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20250811

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250811

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250821

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251027

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20251112

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251117

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251121

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260105

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260105

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260105